🚀 Gate Square Creator Certification Incentive Program Is Live! 
Join Gate Square and share over $10,000 in monthly creator rewards! 
Whether you’re an active Gate Square creator or an established voice on another platform, consistent quality content can earn you token rewards, exclusive Gate merch, and massive traffic exposure! 
✅ Eligibility: 
You can apply if you meet any of the following: 
1️⃣ Verified creator on another platform 
2️⃣ At least 1,000 followers on a single platform (no combined total) 
3️⃣ Gate Square certified creator meeting follower and engagement criteria 
Click to apply now 👉 
Novo Nordisk plans to acquire Metsera for $9 billion, challenging Pfizer's established deal.
Jin10 data reported on October 31 that Danish pharmaceutical company Novo Nordisk (NVO.N) launched a proactive acquisition of obesity drug developer Metsera on Thursday, with an offer of up to $9 billion, aiming to surpass the $7.3 billion deal reached by Pfizer (PFE.N) last month, which may trigger legal actions against the biotech company. The company proposed to acquire Metsera for $56.50 per share in cash, with an additional payment of $21.25 per share upon achieving specific milestones. Metsera stated in a separate announcement that Novo Nordisk's new offer is superior to the Pfizer proposal. According to the protocol, Pfizer currently has four days to modify the original proposal, and if Metsera ultimately determines the new offer is better, it has the right to terminate the agreement with Pfizer. Following the announcement, Metsera's stock price surged over 20%, with a cumulative rise of 78% over the past three months, while Novo Nordisk's stock price in Copenhagen fell nearly 4%.